Vertex and CRISPR Therapeutics’ Casgevy is the first-ever CRISPR/Cas9-based therapy to be approved anywhere in the world. Vertex believes Casgevy has the potential to be a one-time functional ...
Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback